MBX Biosciences Reports Q2 Results and Updates Pipeline
MBX Biosciences reported Q2 results highlighting progress on canvuparatide and MBX 4291 in the obesity pipeline with a robust cash balance.
View filing at SEC.gov →2 most recent filings and news items mentioning MBX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/MBX/news?limit=20"
Pull MBX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayMBX Biosciences reported Q2 results highlighting progress on canvuparatide and MBX 4291 in the obesity pipeline with a robust cash balance.
View filing at SEC.gov →MBX announced sustained one-year efficacy data for once-weekly canvuparatide in chronic hypoparathyroidism, with a 57% responder rate and high 90% retention. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026, supporting advancement toward commercializatio
View filing at SEC.gov →